Ela Pharma

Company Overview

Snapshot

Founded in June 2015 by Roi Paul Nathan and Ilana Nathan, Ela Pharma operates with 1–10 employees. The company has raised $77,000 across two funding rounds. In December 2020, the company secured funding from Smart Funding.

Business overview

Ela Pharma is a biotechnology company focused on developing innovative drugs to treat clinical conditions caused by necrosis. The company's drug-development process utilizes a novel anti-necrosis technology platform. This technology is based on a unique approach that directly inhibits an intracellular proteolytic enzyme crucial in regulating necrosis pathways. Ela Pharma's initial anti-necrosis agents are small molecules designed to inhibit a specific cellular target, demonstrating significant cell necrosis inhibition at low concentrations. The company operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and biotechnology markets.

Company Intelligence Q&A

What is Ela Pharma's core technology?

Ela Pharma's core technology is a novel anti-necrosis platform that directly inhibits an intracellular proteolytic enzyme critical in regulating necrosis pathways. This approach forms the basis for its drug development process.

When was Ela Pharma founded and by whom?

Ela Pharma was founded in June 2015 by co-founders Roi Paul Nathan and Ilana Nathan.

What type of funding did Ela Pharma receive in December 2020?

In December 2020, Ela Pharma secured funding from Smart Funding, as part of a private equity funding round.

What was a significant non-equity funding event for Ela Pharma?

In December 2019, Ela Pharma received a grant from EU Horizon 2020, marking a significant non-equity funding event for the company.

What is the primary focus of Ela Pharma's drug development?

Ela Pharma's drug development primarily focuses on creating anti-necrosis agents, specifically small molecules designed to inhibit a cellular target that plays a critical role in necrosis.